Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts At High Risk of Developing Ebola Virus Disease (EVD)
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Atoltivimab/maftivimab/odesivimab (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Therapeutic Use
- Acronyms EBO-PEP
Most Recent Events
- 28 Feb 2025 New trial record